PharmaResearch is expanding into obstetrics and gynecology by highlighting a regeneration ingredient derived from salmon.
PharmaResearch said on the 7th that it launched Gyner, an adhesive transparent wound dressing based on polynucleotide (PN) that applies DNA optimization technology (DOT).
Gyner can be used on the female perineum and is applied to wound areas with minor bleeding or low exudate to prevent skin damage. In particular, it is designed with adhesiveness and transparency so it can be applied relatively easily to sensitive areas.
The product is meaningful as the first case of expanding DOT PN technology, previously used mainly for skin, into obstetrics and gynecology. The company plans to broaden its application to areas with steady demand for professional care, such as the perineum, to strengthen its position in the related market.
It also moved to secure a clinical foundation. PharmaResearch held an academic program for obstetrics and gynecology clinicians on Mar. 31 and discussed the applicability of DOT PN in obstetrics and gynecology, directions for real-world clinical use, and marketability.
A company official said, "Gyner is a new option for areas that require more delicate care," and added, "We will continue to expand academic exchanges in obstetrics and gynecology and keep introducing products that can help improve women's health and quality of life."
Meanwhile, PharmaResearch develops and sells pharmaceuticals, medical devices, cosmetics, and health functional foods using DOT-based PDRN and PN materials. Its main products include Rejuran, Rejuviel, Conjuran, and Rejuran Cosmetic.